Translating Next-Generation Science Into Transformative Gene TherapiesLearn About Our Programs

Encoded is building an internally developed pipeline of best- and potentially first-in-class therapies focused on pediatric central nervous system (CNS) disorders.

Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Our diversity – whether gender, ethnicity, sexual …

Encoded Therapeutics Highlights Progress in Dravet Syndrome Program and Pipeline Ahead of Company Presentation at 44th Annual J.P. Morgan Healthcare Conference

3 days ago · Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome – Designation recognizes the …

Our Science The precision gene therapies being developed at Encoded are designed to modulate gene expression within specific cell types to potentially address the underlying disease …

Encoded team members are creative, passionate and collaborative. We invite you to join us in our mission to develop transformative therapies by fostering a culture of relentless patient focus, …

Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101 Initial studies will focus on infants and young …

Our lead program is for Dravet syndrome, which is a severe, developmental and epileptic encephalopathy characterized by frequent, treatment-resistant and prolonged seizures, …

Encoded carefully designs clinical studies to assess safety and efficacy of its investigational gene therapies for the treatment of neurological disorders. People considering enrolling their child in …